Corino de Andrade disease: mechanisms and impact on reproduction by Lopes, R. et al.
105Received November 11, 2016
Accepted February 02, 2017
Review
Corino de Andrade disease: mechanisms and impact on reproduction
Rita A Lopes1, Teresa Coelho2, Alberto Barros3,4, Mário Sousa1
1 Laboratory of Cell Biology, Department of Microscopy, Institute of Biomedical Sciences Abel Salazar (ICBAS), 
University of Porto, Portugal
2 Department of Neurophysiology, Research Center of Corino de Andrade (Paramyloidosis), Hospital Centre of 
Porto, Portugal
3 Centre for Reproductive Genetics Prof. Alberto Barros (CGR), Porto, Portugal
4 Department of Genetics - School of Medicine, Institute of Health Research and Innovation, University of Porto
ABSTRACT
Familial amyloid polyneuropathy was first described 
by Corino de Andrade in 1952 in Northern Portugal. It is 
a fatal autosomal dominant neurodegenerative disorder 
characterized by a progression of neurologic symptoms, 
beginning early in the reproductive life. The Transthyretin 
gene mutation originates a mutated protein that 
precipitates in the connective tissue as amyloid deposits. 
This disease is presently named Transthyretin-related 
hereditary amyloidosis. We performed an extensive review 
on this disease based on searches in Medical databases and 
in paper references. In this review, we briefly summarize 
the epidemiology and the mechanisms involved on amyloid 
deposition; we detailed how to evaluate the mechanisms 
implicated on the development of the major signs and 
symptoms associated with reproductive dysfunction; and 
we discuss the mechanisms involved in secondary sexual 
dysfunction after psychological treatments. Treatment of 
the disease is directed towards relieving specific symptoms 
in association with liver transplant, and molecular and 
genetic therapeutics. Although the current clinical trials 
indicate symptoms relief, no data on the reproductive 
function was reported. Thus, preimplantation genetic 
diagnosis is presently the only available technique that 
eradicates the disease as it avoids the birth of new patients.
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INTRODUCTION
Familial amyloid polyneuropathy was first described 
in 1952 by Corino de Andrade in Northern Portugal 
(Andrade, 1952); being presently named Transthyretin-
related hereditary amyloidosis (V30M). It is a chronic 
fatal hereditary autosomal dominant neurodegenerative 
disorder, with a high prevalence in that endemic region 
(1:1000). The progressive sensory, autonomic and 
motor neuropathies eventually leads to cachexia and/or 
cardiovascular collapse, and results in death 10-20 years 
after the onset of symptoms (Sousa et al., 1995; Ando 
et al., 2013). It is caused by a single nucleotide mutation in 
the Transthyretin (TTR) gene (Saraiva et al., 1984; Benson 
& Kincaid, 2007).
Most of the affected individuals are heterozygous 
and thus express both normal and variant TTR. Although 
carriers of the mutation have a circulating mutant protein 
since fetal life, no toxic amyloid deposition occurs until 
adulthood. This disease is thus mainly diagnosed in young 
adults (high penetrance) with less than 40 years of age 
(early-onset), at a similar gender-wise ratio. In these 
patients, 60% develop symptoms between 25-35 years and 
87% before 40 years of age (Saraiva et al., 1984; Benson 
& Kincaid, 2007; Ando et al., 2013). In regions outside 
the endemic area, the V30M mutation has a late-onset 
(after 50 years of age) of symptoms (reduced penetrance) 
and some individuals may remain asymptomatic for 
life. Patients are thus frequently diagnosed after having 
achieved a natural conception (Sousa et al., 1995; Coelho 
et al., 1994; Soares et al., 1999, 2004, 2005).
1. Molecular mechanisms involved in amyloid 
deposition, toxic effects and tissue specificity
The gene that codes for the TTR protein is located on 
chromosome 18. Transthyretin is the plasma transport 
protein for thyroid hormone thyroxin and retinol-binding 
protein/vitamin A. It is made of four monomers that 
associate into dimers and then into a tetramer. Although 
mainly produced by hepatocytes, it is also synthesized 
in the retinal pigment epithelium of the eye and in the 
ventricular choroid plexus of the brain. The TTR protein 
does not cross the blood-brain barrier (BBB) and the 
concentrations found in the cerebrospinal fluid (CSF) are 
much higher than those in the plasma (Saraiva et al., 
1984, 1985; Coelho et al., 1994; Hou et al., 2007; Teixeira 
et al., 2013).
The mutated TTR is originated from a missense point 
mutation in exon 2, that causes the replacement of amino 
acid valine for methionine at position 30. This causes a 
conformational change whose instability facilitates the 
dissociation of the tetramer into monomers. Monomers then 
precipitate in the loose connective tissue and progressively 
self-assemble into amyloid fibrils (Costa et al., 1978; 
Saraiva et al., 1984, 1985; Benson & Kincaid, 2007; Hou 
et al., 2007; Planté-Bordeneuve & Said, 2011; Gasperini & 
Small, 2012; Teixeira et al., 2013). Precipitated monomers 
interact with the cytoplasmic membrane of Schwann cells 
(Figure 1), causing calcium influx, and this intracellular 
increase in calcium induces the release of further calcium 
from calcium stores. The high level of intracellular 
calcium is toxic and promotes an increase in free oxygen 
radical concentration, which then causes membrane 
lipid peroxidation. This is followed by the activation of 
apoptosis mechanisms. Additionally, abnormal TTR also 
precipitates in the loose connective tissue of endoneurium 
capillaries (Figure 1), causing similar injury cell events. 
Injured Schwann cells and endothelial cells then activate 
an inflammatory response. All the phenomena lead to 
progressive demyelination and neuron loss, which is 
aggravated by nerve ischemia due to a compression effect 
(Sousa et al., 2001, 2004; Teixeira et al., 2006; Benson 
& Kincaid, 2007; Hou et al., 2007; Planté-Bordeneuve & 
Said, 2011; Gasperini & Small, 2012).
The disease initiates in the peripheral nervous system 
(PNS). The mutated protein in the PNS originates in the 
circulation and by CFS diffusion. Since the blood-nerve 
barrier (BNB) is much weaker than the BBB, TTR can easily 
traverse the BNB (Sousa et al., 2004). In addition, TTR 
expression was also found in Schwann cells, which would 
enable PNS direct attainment (Murakami et al., 2010). It is 
suspected that cells more resistant to amyloid deposition 
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Figure 1. Typical appearance of peripheral nerves. A, B. Each nerve is surrounded by a dense connective tissue, the 
epineurium (E). Nerves are a group of nerve fibers (arrowheads) disposed into different size aggregates - the nerve fascicles 
(F). Nerve bundles are separated by loose connective tissue, the perineurium (P). Numerous blood vessels (arrows) can 
be seen in the perineurium. Each bundle presents numerous axons surrounded by loose connective tissue, the endoneurium 
(En). In myelinated axons, Schwann cells develop thin cytoplasmic extensions that wrap over the axon surface, creating 
the myelin sheath. The cytoplasmic membrane of the Schwann cell is tightly connected to the axon cytoplasmic membrane, 
controlling axon metabolism through transmembrane channels and pH, providing the ATP necessary for kinesin-continued 
transport of neurotransmitter vesicles along microtubules, and scavenging free toxic oxygen radicals produced during electric 
impulses. The myelin layer is a barrier to most molecules, and only very small liposoluble molecules can traverse the myelin 
sheath. C. In myelinated axons, each nerve fibber consists of an axon (ax) surrounded by the myelin sheath (m) of Shawn 
cells (Sc). Unmyelinated axons are nevertheless surrounded by Schwann cells. D. Myelinated fibers (m), light myelinated 
fibers (Lm) and unmyelinated fibers (um). A-C. Sural nerve, Hemalumen-eosin. D. Sciatic nerve, Osmic acid. Bars: A: 200 
µm; B: 100 µm; C: 9 µm; D: 9 µm.
are surrounded by less connective tissue and/or have larger 
defense mechanisms, as in hepatocytes, the main site of 
TTR synthesis. On the contrary, axons are surrounded by 
large amounts of loose connective tissue and have poor 
defense mechanisms. The beginning of symptoms in the 
body extremities can thus be explained by the fact that 
these axons are very long and distant from the neural 
cell bodies (lack of the appropriate antioxidant systems 
needed to defend against peroxide membrane damage) 
and present more small myelinated and unmyelinated 
fibers (less myelin protection) (Sousa et al., 2004).
2. Molecular mechanisms of the disease
V30M affects both branches of the PNS, somatic and 
autonomic, with different nerve fibers being affected at 
different stages of the disease. In the early stages, the 
smaller nerve fibers (small myelinated and unmyelinated), 
which mediate pain, thermal sensation and autonomic 
function, are affected. As the disease moves on to more 
advanced stages, the larger myelinated fibers (large nerve 
fibers are heavily myelinated and mediate motor strength, 
vibratory and touch sensation) start being impaired and 
destroyed. As the function of the limbs deteriorates, 
the autonomic nervous system also becomes impaired 
by amyloid deposition. Early symptoms correspond to 
neurogenic digestive disturbances. With time, patients 
refer that all they eat is immediately evacuated, which leads 
to cachexia (Andrade, 1952; Coelho et al., 1994; Benson 
& Kincaid, 2007; Hou et al., 2007; Planté-Bordeneuve & 
Said, 2011; Ando et al., 2013).
Besides peripheral neuropathy and gastrointestinal 
impairment, other clinical problems originate from V30M. 
Orthostatic hypotension (Benson & Kincaid, 2007; Planté-
Bordeneuve & Said, 2011; Ando et al., 2013), Nephropathy 
(Lobato et al., 2003; Benson & Kincaid, 2007; Lobato & 
Rocha, 2012; Planté-Bordeneuve & Said, 2011; Ando et al., 
2013), Ocular diseases (Benson & Kincaid, 2007; Cunha-
Vaz, 2009; Beirão et al., 2012, 2013; Planté-Bordeneuve 
& Said, 2011; Ando et al., 2013), Heart diseases (Benson 
& Kincaid, 2007; Planté-Bordeneuve & Said, 2011; Ando 
et al., 2013), and reproductive problems.
3. Problems related to the reproductive system
Patients with V30M develop sexual impairments due to 
psychological and physical problems, with the latter being 
related to peripheral nerve loss and vascular ischemia. 
Sexual responses (Figure 2) are mediated by the coordinated 
action of the PNS: sympathetic, parasympathetic and 
somatic sensory nerves. They have two synapses. The 
first synapse links preganglionic neurons (in the spine) 
to postganglionic neurons (adjacent to the spine), which 
is mediated by the neurotransmitter acetylcholine that 
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acts over nicotinic receptors. The second synapse links 
postganglionic neurons to the target tissue, being mediated 
by neurotransmitters norepinephrine/noradrenaline (or 
epinephrine/adrenaline), that act on adrenergic receptors. 
Parasympathetic nerves have their postganglionic ganglia 
in the pelvis. The neurotransmitter is acetylcholine, that 
acts on cholinergic receptors in target tissues. Vascular 
arterial dilation (penis and clitoris erection) depend of 
parasympathetic nerves, with a simultaneous relaxation 
of smooth muscles of the venous (cavernous) sinusoids 
by means of nitric oxide. The parasympathetic nerves also 
stimulate the vas deferens, seminal vesicles, prostate and 
vaginal glands. The pelvic splanchnic nerve is formed by 
the parasympathetic nerves from the sacral S2-S4 levels 
of the spinal cord (preganglionic neurons) (Meston, 2000; 
Kandeel et al., 2001; McKenna, 2002; Bancroft, 2005; 
Krüger et al., 2005; Azadzoi & Siroky, 2010; Andersson, 
2011; Tezer et al., 2012; Alwaal et al., 2015).
Whereas Reflex Erection arises from direct stimulation 
of the penis and is mediated by parasympathetic nerves, 
Psychogenic Erection is mediated by sympathetic nerves. 
Stimulation of sexual male glands secretion and vaginal 
secretion is also controlled by parasympathetic nerves. 
Emission involves the release of sperm through contraction 
of the gonadal ducts and the sexual glands, and is controlled 
by sympathetic nerves (the hypograstric nerve is formed 
by the sympathetic nerves from the thoracic T11 level up 
to the lumbar L2 level of the spinal cord at preganglionic 
neurons). Uterus, cervix and vagina contractions are 
also controlled by sympathetic nerves. Smooth muscle 
contraction of the vas deferens during ejaculation (release 
of sperm through the urethra) and vaginal contractions 
during orgasm, as well as the contractions of the somatic 
pelvic muscles that accompany the orgasm, are controlled 
by the sacral spinal nerves (the pudendal nerve is formed by 
the spinal nerves from the sacral S2-S4 levels of the spinal 
cord), that in turn convey the genital perineal sensations 
to the brain (efferent and afferent sensory-motor fibers) 
(Meston, 2000; Kandeel et al., 2001; McKenna, 2002; 
Bancroft, 2005; Krüger et al., 2005; Azadzoi & Siroky, 
2010; Andersson, 2011; Tezer et al., 2012; Alwaal et al., 
2015).
Arousal means a psychological sexual anticipation. 
Male arousal leads to erection, whereas in females the 
arousal response is reflected in engorged sexual tissues 
such as nipples, vulva, clitoris, vaginal walls and vaginal 
lubrication. Mental stimuli and physical stimuli such 
as touch, and the internal fluctuation of hormones can 
influence sexual arousal. Sexual dysfunction includes 
any problem experienced by either member of the couple 
during the sexual act that prevents them from having a 
pleasant and positive sexual experience (Meston, 2000; 
Kandeel et al., 2001; McKenna, 2002; Bancroft, 2005; 
Krüger et al., 2005; Azadzoi & Siroky, 2010; Andersson, 
2011; Tezer et al., 2012; Alwaal et al., 2015).
In V30M patients, sexual dysfunction is believed to 
be associated with problems concerning the autonomic 
nervous system, followed by psychogenic responses. 
In men, the most common abnormalities related to the 
reproductive system are erectile dysfunction and retrograde 
ejaculation. Normally, the urethral sphincter contracts 
before ejaculation forcing the semen to exit via the urethra. 
When the sphincter does not function properly, retrograde 
ejaculation may occur, with semen being introduced into 
the bladder. The urethral sphincter is composed of smooth 
muscle and is thus controlled by the autonomic nervous 
system. The sympathetic nervous system maintains 
tonic contractions of the urethral muscle, whereas the 
parasympathetic nervous system relaxes the urethral 
sphincter muscle during micturition. The parasympathetic 
activity is responsible for bladder contraction and enables 
the urethral sphincter to open and urine to be expelled into 
the urethra. The sympathetic activity leads to contraction 
and closure of the sphincter. Moderate bladder distension 
inhibits parasympathetic activity to enable the bladder to 
be normally filled. When the bladder is full, the afferent 
activity conveys this information to the brain and this leads 
to an increase of the parasympathetic tone, together with 
a decrease in sympathetic activity, causing the urethral 
sphincter muscle to relax and the bladder to contract, 
which is followed by micturition (Hita Villaplana et al., 
1977; Jung et al., 2012).
In men, erectile dysfunction (controlled by 
parasympathetic nerves) can be one of the first signs 
of V30M (Andrade, 1952), and it is also related to the 
autonomic neuropathy. Problems in ejaculation (controlled 
by sympathetic nerves) can also be present. Besides 
retrograde ejaculation (see above) they can also develop 
secretory azoospermia due to atrophy of the seminiferous 
tubules, caused by amyloid deposits in the interstitial loose 
connective tissue around small vessels (Andrade, 1952). 
These men need psychological support, and there are 
several drugs that help in erection.
Female Sexual dysfunction affects about 42% of V30M 
patients. It is due to pelvic nerve injury (neuropathy) 
caused by destruction of genital myelinated fibers. In this 
area, amyloid deposition induces nerve loss and decreased 
blood flow (amyloid causes vessel degeneration) (Alves 
et al., 1997; Gomes et al., 2011, 2012; Oliveira-e-Silva 
et al., 2013). Among the symptoms associated with this 
condition there are reductions on the number of sexual 
stimuli received by the individual, lubrication deficiencies, 
lack of sexual desire (due to difficulties in peripheral 
stimulation) and arousal, painful intercourse, difficulties 
concerning orgasms and sexual dissatisfaction. More 
specifically, there is decreased genital area sensation 
(decreased sexual pleasure stimulation feelings), clitoral 
blood flow (decreased erection and sensibility; decreased 
vaginal congestion and dilation), contractile capacity 
(decreased uterine and vaginal contractions), and 
glandular secretion (decreased lubrication causes genital 
discomfort). Recurrent urinary tract infections, vaginal and 
uterus prolapse, and urinary incontinence - namely coital 
urinary incontinence (due to detrusor hypo-contractility 
by loss of parasympathetic nerve stimulation of this 
smooth muscle of the bladder wall), aggravate the loss of 
sexual drive (decreased mental arousal), and thus appear 
associated with dyspareunia (painful intercourse) and 
sexual dissatisfaction. These patients need psychological 
support, and there are several pelvic and vaginal therapies 
that should be introduced, besides surgical corrections of 
prolapses and incontinence (Gomes et al., 2011, 2012).
Sexual dysfunction is directly associated to disease 
stage and can be aggravated by the medication taken by 
the patients. Known medications with a negative impact 
on sexual function are anti-depressives, anxiolytics, 
antiepileptics and anti-hypertensives. Affected patients 
become psychological fragile, as they know they have 
a potential fatal disease and they are not sexually 
satisfactory to their partner. This causes loss of sexual 
motivation as they feel less feminine/masculine, that their 
body is damaged, unhappy, frustrated, shame, self-image 
degradation, and failure to meet personal expectations.
Several medications are used to counteract these 
psychological problems, but on the other hand there are 
side-effects reflecting on sexual performance. Anxiolytics 
stimulate gamma-aminobutyric receptors (GABA), and 
sexual side-effects include decreased libido (decreased 
gland secretion) and erection (penis and clitoris), which 
is accomplished through anticholinergic (parasympathetic 
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Figure 2. Phases of the sexual response. Control mechanisms by the 
peripheral nervous system, somatic and autonomic (sympathetic and 
parasympathetic).
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nerves: erection, gland secretion) and antiadrenergic 
(sympathetic nerves: orgasm) effects (Tallman et al., 
2002). Anti-depression agents increase serotonin activity, 
which inhibits acetylcholine and norepinephrine receptors, 
thus inhibiting their functions in arousal, erection and 
orgasm; they have anticholinergic effects (involved 
in erection, male and vaginal lubrication); they cause 
dopamine blockade (dopamine increases sexual arousal 
and enhance penile erection); nitric oxide inhibition 
(involved in erection); and increase prolactin secretion (loss 
of male arousal, erection, orgasm, retrograde ejaculation: 
hyperprolactinemia impairs luteinizing hormone (LH) 
release, which causes decreased testosterone production, 
blocks dopamine actions, increases serotonin secretion 
and blocks adrenergic receptors) (Baldwin & Mayers, 2003; 
Buvat, 2003). Antiepileptics are used to treat sensitive 
disorders and pain, with side-effects causing loss of sexual 
drive, arousal, erection, gland secretion and orgasm. 
Gabapentin and Pregabalin are anticonvulsants used to 
treat neuropathic pain. Although they stimulate GABA 
actions, their main action is to bind to voltage-gated Ca2+ 
channels of synapses, inhibiting neurotransmitter release 
in spinal cord neurons (Kaufman & Struck, 2011). Anti-
hypertensives can also cause sexual dysfunction as a side-
effect. The effects on erection are supposed to derive from 
vascular supply impairment and vascular smooth muscle 
contraction; of adrenergic receptors block (sympathetic 
nerves: emission and contraction); and cholinergic 
receptors block (parasympathetic nerves: erection and 
gland secretion). Some also alter serotonin action (Manolis 
& Doumas, 2012; Nunes et al., 2012).
4. Medical interventions to avoid disease 
transmission
Current V30M treatments are directed towards relieving 
specific symptoms, such as pain, infections, cardiovascular 
problems, kidney failure, bladder dysfunction and genital 
problems. However, efforts have been made to develop 
new treatment modalities in order to eradicate or halt the 
progression of the disease.
4.1. Preimplantation genetic diagnosis
Given that this disease is hereditary and autosomal 
dominant, each patient has at least one parent suffering 
from the condition. As the great majority of the carriers are 
heterozygotes for the disease, they have a 50% chance of 
passing it on to their children if only one parent is affected 
or a 75% chance when both parents are affected. Besides 
social teaching (couple decision to avoid conception), 
the only way to halt transmission of the disease is the 
medical termination of pregnancy after a positive Prenatal 
diagnostic test (Yamashita et al., 2009) or embryo selection 
after preimplantation genetic diagnosis (PGD) (Carvalho 
et al., 2001; Almeida et al., 2005; Valdrez et al., 2014).
The PGD technique enables the detection of the 
genetic defect in embryos conceived by intracytoplasmic 
sperm injection, and thus enables to choose the non-
affected embryo for uterine transfer. Preimplantation 
genetic diagnosis (Figure 3) is performed following a 
sequence of delicate steps. First, the woman is treated 
with subcutaneous administration of a gonadotrophin-
releasing hormone antagonist, to suppress ovary function. 
Growth of several early antral follicles is then stimulated 
with recombinant follicle-stimulating hormone (Pinto et al., 
2009). It takes around 8-10 days for the follicles to reach 
17mm. When they reach this size, the patient is injected 
with human chorionic gonadotrophin (HCG) to stimulate 
the final oocyte maturation and simulate the LH peak. Up 
to 36 hours after this procedure, follicles are aspirated 
from the ovary by guided ultrasound. Now, the woman 
is also given endovaginal progesterone pills to enable 
endometrium differentiation and induce an implantation 
window.
Aspirated follicles are incubated for 2h and then 
cumulus cells are removed by hyaluronidase treatment. 
After 2h of incubation, denuded oocytes are microinjected 
with a selected sperm (Tesarik et al., 1994; Tesarik & 
Sousa, 1995). Sperm are obtained by masturbation 
(ejaculate), urine collection (in retrograde ejaculation), 
electroejaculation (in anejaculation) (Barros et al., 1998), 
or testicular aspiration (in azoospermia or when the quality 
of sperm retrieved by the other methods is insufficient) 
(Sousa et al., 2002). After collection, sperm is submitted 
to a differential gradient centrifugation to select the most 
morphological normal sperm (simulates vaginal and cervix 
selection). Then, sperm are incubated in capacitating 
medium (simulates uterine milieu) and after 1h the most 
morphological normal and rapid progressive sperm are 
chosen for injection. Microinjection is performed in an 
inverted microscope with a heated stage, one spermatozoon 
per oocyte (Figure 3).
After microinjection, oocytes are incubated in 
sequential embryo culture media (simulates tubar and 
uterine milieu). The day after injection, oocytes are 
observed to select those which are normally fertilized 
(presence of two polar bodies and two pronuclei, which 
indicates oocyte activation and meiosis completion by the 
oocyte). When embryo development is normal, at day 2 
they show 2-4 blastomeres and at day 3 they will present 
6-8 cells (Vandervorst et al., 1998). Only day 3 embryos 
with less than 25% of fragments and with similar sized 
blastomeres are selected for embryo biopsy. Embryo 
biopsy is performed in the inverted microscope. A hole on 
the oocyte zona pellucida is obtained with the assistance 
of a computer-controlled laser beam. After that, a biopsy 
micropipette enters the perivitelline space and aspirates 
1-2 blastomeres (Figure 3). While the embryo returns to 
the incubator, each blastomere is transferred to a PCR 
tube and transported to a Genetic reference laboratory. 
There, the DNA of each blastomere is isolated and the 
mutation is screened. After two days, the genetic result 
is given (Carvalho et al., 2001). At that time (day 5 after 
fertilization), cultured viable embryos have developed 
to the blastocyst stage (Gardner et al., 2000). Only 
those blastocysts with absent mutation are transferred 
to the uterine cavity. Alternatively, embryo biopsy can 
be performed at the blastocyst stage (trofectoderme 
biopsy) and embryos are frozen. After the genetic result, 
blastocysts are thawed and transferred in a natural cycle. 
Presently, blastocyst biopsy is the preferable approach in 
cases when at least four high quality embryos are obtained 
at day 3 of culture (Figure 4). Pregnancy is evaluated 
by the rise of serum ß-HCG about 12 days after embryo 
transfer. Overall, the live-birth delivery rate is about 48%.
This procedure has proven to be quite useful for couples 
affected by the disease and that wish to conceive a healthy 
child without wanting the termination of pregnancy. These 
two benefits as well as avoiding the future suffering of the 
child are the three main reasons that lead V30M carriers to 
use PGD when conceiving their offspring.
4.2. Medical interventions to improve quality of 
life
Except for PGD, all other techniques do not avoid the 
existence of the disease but can merely slow down the 
production and deposition of the amyloid fibrils in the PNS 
of patients to improve their quality of life. These include 
organ transplantation (Furtado, 2000; Sousa et al., 2004; 
Benson & Kincaid, 2007; Hou et al., 2007; Lobato & Rocha, 
2012; Beirão et al., 2012, 2013; Ando et al., 2013; Castaño 
et al., 2015), stabilizer agents (Tafamidis: prevent TTR from 
dissociating into monomers) (Coelho et al., 2012, 2013), 
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Figure 3. Live images observed at the inverted microscope. Preimplantation genetic diagnosis. A. Selection of a single, 
morphologically normal spermatozoon (head-h; tail-f) with a 3D forward progressive motility in culture medium (mp) 
supplemented with PVP to decrease spermatozoon velocity. Microinjection pipette (mi). B. Aspiration of the selected 
spermatozoon (arrow) into the microinjection pipette (mi). C. Immobilization of the selected spermatozoon (arrow) in PVP 
(pvp) by crashing (arrowhead) the distal microtubules of the flagellum. D. Cumulus-oocyte complex of the aspirated ovarian 
follicle. The oocyte (o) is coated by granulosa cells (gc) and encircled by follicular cells (fc) of the cumulus oophorus. E. 
Mature metaphase II oocyte after denudation of the cumulus and granulosa cells. Note the perivitelline space (pvs), the 
first polar body (pb1) and the glycoprotein oocyte coat, the zona pellucida (zp) F. For microinjection, the oocyte is held by a 
contention micropipette (mc) with the first polar body at 3 (F) or 6 (G) o’clock. The microinjection pipette is penetrating the 
zona pellucida. The spermatozoon is at the distal border of the microinjection pipette, head first (arrow). G. Penetration of 
the oocyte membrane (arrowhead) by the microinjection pipette. H. The spermatozoon (arrow) is released in the ooplasm. 
I. Extrusion of the microinjection pipette, leaving the spermatozoon in the ooplasm (arrow). The furrow of the oocyte is 
still visible (arrowhead). J. The day after microinjection the oocyte shows signs of normal fecundation as revealed by the 
presence of the second polar body (pb2) and of both pronuclei (arrowheads). K. At the second day after microinjection 
the zygote cleaved into an embryo with 4 blastomeres (b). L-P. Successive images of the embryo biopsy. Three days after 
microinjection the embryo has 8 blastomeres. After opening a small hole in the zona pellucida, the embryo biopsy pipette 
(mb) enters the perivitelline space and gently aspirates two blastomeres (arrowhead). Q. Extrusion (arrowhead) of the two 
blastomeres to the surrounding medium. R. The embryo is left in culture with the evident zona pellucida hole (arrowhead). 
S. Note the nuclei of the isolated blastomeres (arrowheads). The diameter of the oocyte is about 110 µm.
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Figure 4. Live images observed at the inverted microscope. Preimplantation genetic diagnosis. Trophectoderm biopsy. A. 
Note blastocyst retraction and the hole made by the laser beam. B. Note blastocyst expansion and the beginning of hatching 
(arrowhead). The biopsied cells (arrow) are inside the biopsy micropipette (mb). C. Full blastocyst expansion. Note biopsied 
cells (arrow) outside the biopsy micropipette.
gene therapy using antisense oligonucleotides (ASO: 
cause nuclear degradation of the mutated mRNA (Castaño 
et al., 2015; Niemietz et al., 2015), gene therapy using 
small interference RNA (siRNA: block translation of the 
mutated mRNA) (Coelho et al., 2013; Castaño et al., 2015; 
Niemietz et al., 2015; Wittrup & Lieberman, 2015), and 
amyloid removers (Castaño et al., 2015). Transplantation 
did not improve erectile dysfunction but ameliorated 
urinary incontinence. Clinical trials with Tafamidis, ASO 
and siRNA revealed a significant delay in the progression 
of PNS symptoms but data on sexual dysfunction has not 
been reported. Research is in course to develop synthetic 
components that will be able to repair the mutated DNA. 
Only this technique, if administered early in life after 
screening, would greatly ameliorate quality of life. But to 
halt the disease as with PGD, it will be necessary to change 
the germ cell pool, and for now this is only possible in men, 
as they possess stem cells in the germinal epithelium.
CONCLUSION
Treatment of V30M remains directed towards relieving 
specific symptoms in association with liver transplant, 
molecular and genetic therapeutics. This disease has a 
substantial clinical impact on reproductive performance, 
and current treatments do not elicit sexual improvement. 
Thus, PGD remains the only available technique to eradicate 
the disease, as it avoids the birth of new patients.
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